Protective antibodies against human parainfluenza virus type 3 infection
Human parainfluenza virus type III (HPIV3) is a common respiratory pathogen that afflicts children and can be fatal in vulnerable populations, including the immunocompromised. There are currently no effective vaccines or therapeutics available, resulting in tens of thousands of hospitalizations per...
Main Authors: | Jim Boonyaratanakornkit, Suruchi Singh, Connor Weidle, Justas Rodarte, Ramasamy Bakthavatsalam, Jonathan Perkins, Guillaume B.E. Stewart-Jones, Peter D. Kwong, Andrew T. McGuire, Marie Pancera, Justin J. Taylor |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2021.1912884 |
Similar Items
-
Parainfluenza virus infections in a tropical city: clinical and epidemiological aspects
by: Mariana Mota Moura Fé, et al. -
Rhabdomyolysis due to parainfluenza 3 virus infection: Case report and review of literature
by: Radhika Kolpuke, et al.
Published: (2019-01-01) -
Human Parainfluenza Type 4 Infections, Canada
by: Marie-Louise Vachon, et al.
Published: (2006-11-01) -
Epidemiology and clinical severity of the serotypes of human parainfluenza virus in children with acute respiratory infection
by: Le Wang, et al.
Published: (2023-10-01) -
Human parainfluenza virus 3 field strains undergo extracellular fusion protein cleavage to activate entry
by: Kyle Stearns, et al.
Published: (2024-11-01)